Related Experiment Videos
[In vitro effects of epidermal growth factor (EGF) on growth of urological malignant tumor cells]
T Hattori1, Y Terashima, M Hara
1Department of Urology, Nippon Medical School.
Abstract:
It is well known that Epidermal Growth Factor (EGF) is a cell-regulating factor for variety of tissues in vitro including normal and malignant cells. Furthermore, Takano et al reported that a decreased expression of EGF receptor in clones of human cancer KB cell line might be one of the pleiotropic properties of multidrug-resistant cells. However, both the influence of EGF on human urological cancer cell lines and the relation between EGF receptors and sensitivities of antitumor drugs on these cell lines have not been fully described. We have studied the effects of EGF on growth of 4 transitional carcinoma cell lines of bladder (TCCaB), 1 squamous cell carcinoma cell line of bladder (SCCaB), 5 renal cell carcinoma cell lines (RCC) and 3 prostatic carcinoma cell lines (CaP), as well as the relationship between the number of EGF receptors and drug sensitivities of these cell lines in vitro against methotrexate, vinblastine, adriamycin, cisplatin and etoposide (VP16). The present results determined by the in vitro colony forming efficiency method showed that exogenous addition of EGF to cell cultures at 0.1 ng/ml stimulated the growth of SCCaB by 169.0%, and at 1 ng/ml inhibited that of RCC by 2.9%-79.0%, relative to control. The more EGF receptors by 125I-EGF binding assay, the higher inhibition of VP16 on the growth of these cell lines. These results suggested that EGF stimulated the growth of SCCaB and inhibited the growth of RCC in vitro, and we found that these phenomena were correlated with neither the number of EGF receptors nor affinities of that receptors.(ABSTRACT TRUNCATED AT 250 WORDS)
Insights
Epidermal Growth Factor (EGF) impacts urological cancers, stimulating squamous cell carcinoma growth while inhibiting renal cell carcinoma. EGF receptor levels correlated with etoposide sensitivity in these cancer cell lines.
Area of Science:
- Oncology
- Cell Biology
- Pharmacology
Background:
- Epidermal Growth Factor (EGF) is a known regulator of cell growth in various tissues.
- Previous research suggests a link between EGF receptor expression and multidrug resistance in cancer cells.
- The specific effects of EGF on human urological cancers and its relation to drug sensitivity remain largely undefined.
Purpose of the Study:
- To investigate the influence of EGF on the growth of human bladder, renal, and prostate cancer cell lines in vitro.
- To explore the relationship between the number of EGF receptors and the sensitivity of these cell lines to common antitumor drugs.
Main Methods:
- Utilized in vitro colony forming efficiency assays to assess cell growth.
- Employed 125I-EGF binding assays to quantify EGF receptor expression.
- Tested sensitivity to methotrexate, vinblastine, adriamycin, cisplatin, and etoposide (VP16).
Main Results:
- EGF (0.1 ng/ml) stimulated squamous cell carcinoma of the bladder (SCCaB) growth by 169.0%.
- EGF (1 ng/ml) inhibited renal cell carcinoma (RCC) growth by 2.9%-79.0%.
- Higher EGF receptor expression correlated with increased inhibition of cell growth by etoposide (VP16).
Conclusions:
- EGF demonstrates differential effects on urological cancer cell lines, stimulating SCCaB and inhibiting RCC growth in vitro.
- The observed growth effects of EGF were not directly correlated with EGF receptor number or affinity.
- A positive correlation was found between EGF receptor expression and sensitivity to etoposide (VP16).